tradingkey.logo

BioLife Solutions Inc

BLFS
查看詳細走勢圖
24.900USD
-0.510-2.01%
收盤 12/26, 16:00美東報價延遲15分鐘
1.19B總市值
虧損本益比TTM

BioLife Solutions Inc

24.900
-0.510-2.01%
盤中分時
1分
30分
1小時
日k
週k
月k
日k

今天

-2.01%

5天

-0.68%

1月

-6.67%

6月

+15.92%

今年開始到現在

-4.08%

1年

-7.88%

查看詳細走勢圖

TradingKey BioLife Solutions Inc股票評分

單位: USD 更新時間: 2025-12-26

操作建議

BioLife Solutions Inc當前公司基本面數據相對非常健康,增長潛力很大。當前估值合理,在醫療設備與耗材行業排名17/207位。機構持股佔比非常高,近一個月多位分析師給出公司評級為買入。最高目標價32.10。中期看,股價處於平穩狀態。近一個月,市場表現較差,但公司基本面和技術面得分較高。目前股價在壓力位和支撐位之間,可以做區間波段操作。

BioLife Solutions Inc評分

相關信息

行業排名
17 / 207
全市場排名
89 / 4563
所屬行業
醫療設備與耗材

壓力支撐

由於公司未披露,未能獲取相關數據

多維評測

本期評分
上期評分

分析師目標

基於 10 分析師
買入
評級
32.100
目標均價
+28.66%
漲幅空間
數據免責聲明:分析師評級與目標價由LSEG提供,僅供參考,不應當作投資建議

BioLife Solutions Inc亮點

亮點風險
BioLife Solutions, Inc. is a developer and supplier of cell processing tools and services for the cell and gene therapy (CGT) market. The Company facilitates the commercialization of new therapies by supplying solutions that maintain the health and function of biologic materials during collection, development, manufacturing and distribution. Its CryoStor freeze media and HypoThermosol hypothermic storage media are optimized to preserve cells in the regenerative medicine market. Its Sexton cell processing product line includes human platelet lysates (hPL) for cell expansion. Its CellSeal cryogenic vials, which are rigid containers used in cell and gene therapy (CGT). Its CryoCase cryo-compatible transparent rigid containers are designed for closed-system fill and retrieval, and automated cell processing machines. The Company’s ThawSTAR product line is composed of a family of automated thawing devices for frozen cell and gene therapies packaged in cryovials and cryobags.
業績增長期
公司處於發展階段,最新年度總收入82.25M美元
估值低估
公司最新PE估值-448.89,處於3年歷史低位
機構減倉
最新機構持股49.86M股,環比減少1.47%
PRFDX持倉
明星投資者PRFDX持倉,最新持倉80.95K股

BioLife Solutions Inc新聞

即將為您帶來更多新聞,敬請期待。 。 。

財務指標

每股收益

由於公司未披露,未能獲取相關數據

營業總收入

由於公司未披露,未能獲取相關數據

BioLife Solutions Inc簡介

BioLife Solutions, Inc. is a developer and supplier of cell processing tools and services for the cell and gene therapy (CGT) market. The Company facilitates the commercialization of new therapies by supplying solutions that maintain the health and function of biologic materials during collection, development, manufacturing and distribution. Its CryoStor freeze media and HypoThermosol hypothermic storage media are optimized to preserve cells in the regenerative medicine market. Its Sexton cell processing product line includes human platelet lysates (hPL) for cell expansion. Its CellSeal cryogenic vials, which are rigid containers used in cell and gene therapy (CGT). Its CryoCase cryo-compatible transparent rigid containers are designed for closed-system fill and retrieval, and automated cell processing machines. The Company’s ThawSTAR product line is composed of a family of automated thawing devices for frozen cell and gene therapies packaged in cryovials and cryobags.
公司代碼BLFS
公司BioLife Solutions Inc
CEODe Greef (Roderick)
網址https://www.biolifesolutions.com/

常見問題

BioLife Solutions Inc(BLFS)的當前股價是多少?

BioLife Solutions Inc(BLFS)的當前股價是 24.900。

BioLife Solutions Inc 的股票代碼是什麼?

BioLife Solutions Inc的股票代碼是BLFS。

BioLife Solutions Inc股票的52週最高點是多少?

BioLife Solutions Inc股票的52週最高點是29.620。

BioLife Solutions Inc股票的52週最低點是多少?

BioLife Solutions Inc股票的52週最低點是19.100。

BioLife Solutions Inc的市值是多少?

BioLife Solutions Inc的市值是1.19B。

BioLife Solutions Inc的淨利潤是多少?

BioLife Solutions Inc的淨利潤為-20.18M。

現在BioLife Solutions Inc(BLFS)的股票是買入、持有還是賣出?

根據分析師評級,BioLife Solutions Inc(BLFS)的總體評級為買入,目標價格為32.100。

BioLife Solutions Inc(BLFS)股票的每股收益(EPS TTM)是多少

BioLife Solutions Inc(BLFS)股票的每股收益(EPS TTM)是-0.055。
KeyAI